trending Market Intelligence /marketintelligence/en/news-insights/trending/n-m4mmk5n0chgeuathwlig2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Ono Pharmaceutical secures license for antibody discovery platform

South Korean Multichannel Industry To Survive With Right Strategies

South Korean Telcos Drive Next Wave Of Growth Through Home IoT Opportunities

Mining Exploration Insights: Financing Falls To 8-Month Low In October

ITU Clears The Way For 17.25 GHz Of New mmWave Spectrum For 5G

Ono Pharmaceutical secures license for antibody discovery platform

Ono Pharmaceutical Co. Ltd. secured a global license for Ligand Pharmaceuticals' OmniAb platform to discover antibody-based treatments for diseases.

The agreement provides for the OmniRat, OmniMouse and OmniFlic platforms to formulate fully human mono- and bispecific antibodies.

Ligand will receive an undisclosed annual payment for access to the platform as well as milestone-related payments and royalty on sales of products derived from the platform.